BioSpace News Archive

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announced outstanding clinical results for its total hip arthroplasty (THA) portfolio in both the National Joint Registry for England, Wales and Northern Ireland (NJR) and the the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR

Medtronic plc (NYSE: MDT) announced that the U.S. Food and Drug Administration (FDA) has cleared the use of navigated interbody and Midas Rex™ high speed drills with the Mazor™ Robotic Guidance System earlier than originally anticipated.

Blue Cross Blue Shield of Massachusetts (“Blue Cross”) today announced two new initiatives designed to provide additional support to members living with substance use disorder. The company has contracted with AWARE

Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with Illumina Inc. and the integration of automated interpretation into Illumina’s TruSight™ Software Suite for rare genetic diseases

BRAINBox Solutions today announced it is beginning enrollment in its pivotal clinical trial, HeadSMART II (Head injury Serum markers and Multi-modalities for Assessing Response to Trauma), of the company’s concussion diagnostic and prognostic test, BRAINBox TBI.

The Buck Institute for Research on Aging is pleased to announce the appointment of Malene Hansen PhD to the position of Professor and Chief Scientific Officer.

New Hampshire and the City of Chicago, among others, are using the Salesforce Platform to more safely and efficiently manage their vaccine programs at scale

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, successfully hosted the first session of its virtual investor mini-series themed “Delivering on the Promise of Synthetic Biology.”

Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer and head, translational medicine

Analytics 4 Life today announced the appointment of Scott Burger to Chief Commercial Officer and Vice President.